𝔖 Bobbio Scriptorium
✦   LIBER   ✦

4019 POSTER Phase III, randomized, open-label study of triweekly docetaxel (tT) vs. biweekly docetaxel (bT) as treatment for advanced hormone refractory prostate cancer (HRPC): findings from an interim safety analysis

✍ Scribed by P. Kellokumpu-Lehtinen; T. Joensuu; P. Hervonen; P. Nyandoto; T. Luukkaala; A. Hemminki; R. Asola; M. Luukkaa; I. Lehtinen; H. Joensuu


Book ID
118625929
Publisher
Elsevier Science
Year
2007
Tongue
English
Weight
59 KB
Volume
5
Category
Article
ISSN
1359-6349

No coin nor oath required. For personal study only.